Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astegolimab versus placebo in COPD
NL-OMON59731Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Astegolimab with Placebo (2 arms). Primary endpoint: Annualized rate of moderate and severe COPD exacerbations. Started Mar 2022; status: completed.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON59731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59731.